Compare LW & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | KRYS |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | LW | KRYS |
|---|---|---|
| Price | $50.86 | $271.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $56.14 | ★ $257.45 |
| AVG Volume (30 Days) | ★ 3.0M | 296.6K |
| Earning Date | 12-19-2025 | 02-13-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | 9.13 | ★ 275.72 |
| EPS | 2.78 | ★ 6.66 |
| Revenue | ★ $6,473,600,000.00 | $373,164,000.00 |
| Revenue This Year | $4.26 | $36.36 |
| Revenue Next Year | N/A | $42.15 |
| P/E Ratio | ★ $18.06 | $40.94 |
| Revenue Growth | 2.35 | ★ 54.51 |
| 52 Week Low | $39.79 | $122.80 |
| 52 Week High | $67.07 | $295.98 |
| Indicator | LW | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 52.11 |
| Support Level | $44.71 | $260.03 |
| Resistance Level | $48.15 | $286.52 |
| Average True Range (ATR) | 1.42 | 10.98 |
| MACD | 1.06 | -2.94 |
| Stochastic Oscillator | 87.62 | 36.15 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.